sur ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics Partners with Eurobio Scientific for Exclusive Distribution in France
ABL Diagnostics (Euronext Paris: ABLD), a leader in molecular diagnostics, has signed an exclusive agreement with Eurobio Scientific (Euronext Growth Paris: ALERS) for distributing its VELA product line in the French public hospital sector. This collaboration allows ABL to improve access to next-generation sequencing and viral genotyping solutions, prioritizing local service.
The agreement involves transferring certain customer responsibilities to Eurobio, while others remain under ABL's management. Eurobio has a long history with the VELA line, bolstering this strategic move. The partnership fits into ABL’s broader European expansion strategy, following recent similar announcements. VELA’s products focus on virology applications, such as HIV and HCV genotyping.
CEO Chalom Sayada emphasizes the agreement’s alignment with ABL's market growth goals, ensuring comprehensive yet tailored service.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABL DIAGNOSTICS